AbbVie Quietly Solved Its Biggest Problem—Now What?
AbbVie posted strong Q2 revenue and EPS growth, and despite a post-earnings dip tied to the Apogee Therapeutics deal, analysts and dividend strength support shares reaching $300.
Read the full story at MarketBeat News Feed →